Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers &
Description
Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)
The biosimilars market was valued at US$ 18,435.89 million in 2021 and is expected to reach US$ 136,069.53 million by 2028; it is estimated to record a CAGR of 34.8% from 2022 to 2028.
The biosimilars market growth is attributed to the increasing prevalence of chronic diseases, the cost-effectiveness of biosimilar drugs, and the increase in approvals of biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing restrain the biosimilars market growth.
The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to bring safe and effective biosimilars to market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.
A few recent approvals of biosimilar products are mentioned in the following table.
Thus, the rising approvals of biosimilars are propelling the biosimilars market growth.
Collaborations of Market Players for Biosimilar Production and Clinical Trials to Fuel Biosimilar Market Growth During Forecast Period.
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.
By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.
Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.
There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:
In January 2022, Samsung Biologics and Biogen entered a joint venture, forming Samsung Bioepis. Samsung Bioepis launched biosimilars of etanercept, adalimumab, infliximab, and trastuzumab in Europe, with others in the pipeline. It has also entered into many commercialization partnerships.
In March 2021, The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Inc. to launch ten projects, announced that it had received funding to support innovative approaches to enhance the processes related to appropriate biosimilar adoption in oncology.
In September 2019, Henlius announced a strategic collaboration with Ascentage Pharma to conduct clinical trials of the combination therapy between Rituximab Injection, the first launched product by Henlius, and APG-2575, a novel and orally administered Bcl-2 selective inhibitor developed by Ascentage Pharma, for the treatment of chronic lymphocytic leukemia (CLL) in China.
In June 2019, STADA and Xbrane Biopharma expanded their biosimilar collaboration to evaluate potential collaboration on additional products. The two companies stated that they will focus on biosimilars of originator products that will face patent expiry from 2025 to 2030.
Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
Disease Indication-Based Insights
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2021. The market for the autoimmune diseases segment is likely to grow at the highest rate during the forecast period.
Drug Class-Based Insights
The biosimilars market, based on drug class, is segmented into Granulocyte Colony-stimulating Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-stimulating Stimulating Agents, and Others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 35.8% during the forecast period.
Route of Administration -Based Insights
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 36.0% during the forecast period.
End User-Based Insights
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2021, whereas the homecare segment is expected to register the highest CAGR of 36.6% during the forecast period.
World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Library of Medicine, National Psoriasis Foundation, Statistisches Bundesamt (Destatis), International Diabetes Federation (IDF), and Cardinal Health are a few of the major primary and secondary sources referred to while preparing the report on the biosimilars market.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the biosimilars market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the biosimilars market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
The biosimilars market was valued at US$ 18,435.89 million in 2021 and is expected to reach US$ 136,069.53 million by 2028; it is estimated to record a CAGR of 34.8% from 2022 to 2028.
The biosimilars market growth is attributed to the increasing prevalence of chronic diseases, the cost-effectiveness of biosimilar drugs, and the increase in approvals of biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing restrain the biosimilars market growth.
The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to bring safe and effective biosimilars to market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.
A few recent approvals of biosimilar products are mentioned in the following table.
Thus, the rising approvals of biosimilars are propelling the biosimilars market growth.
Collaborations of Market Players for Biosimilar Production and Clinical Trials to Fuel Biosimilar Market Growth During Forecast Period.
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.
By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.
Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.
There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:
In January 2022, Samsung Biologics and Biogen entered a joint venture, forming Samsung Bioepis. Samsung Bioepis launched biosimilars of etanercept, adalimumab, infliximab, and trastuzumab in Europe, with others in the pipeline. It has also entered into many commercialization partnerships.
In March 2021, The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Inc. to launch ten projects, announced that it had received funding to support innovative approaches to enhance the processes related to appropriate biosimilar adoption in oncology.
In September 2019, Henlius announced a strategic collaboration with Ascentage Pharma to conduct clinical trials of the combination therapy between Rituximab Injection, the first launched product by Henlius, and APG-2575, a novel and orally administered Bcl-2 selective inhibitor developed by Ascentage Pharma, for the treatment of chronic lymphocytic leukemia (CLL) in China.
In June 2019, STADA and Xbrane Biopharma expanded their biosimilar collaboration to evaluate potential collaboration on additional products. The two companies stated that they will focus on biosimilars of originator products that will face patent expiry from 2025 to 2030.
Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
Disease Indication-Based Insights
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2021. The market for the autoimmune diseases segment is likely to grow at the highest rate during the forecast period.
Drug Class-Based Insights
The biosimilars market, based on drug class, is segmented into Granulocyte Colony-stimulating Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-stimulating Stimulating Agents, and Others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 35.8% during the forecast period.
Route of Administration -Based Insights
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 36.0% during the forecast period.
End User-Based Insights
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2021, whereas the homecare segment is expected to register the highest CAGR of 36.6% during the forecast period.
World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Library of Medicine, National Psoriasis Foundation, Statistisches Bundesamt (Destatis), International Diabetes Federation (IDF), and Cardinal Health are a few of the major primary and secondary sources referred to while preparing the report on the biosimilars market.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the biosimilars market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the biosimilars market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
217 Pages
- 1. Introduction 30
- 1.1 Scope of the Study. 30
- 1.2 The Insight Partners Research Report Guidance. 30
- 1.3 Market Segmentation. 31
- 1.3.1 Global Biosimilars Market – by Disease Indication. 33
- 1.3.2 Global Biosimilars Market – by Drug class. 33
- 1.3.3 Global Biosimilars Market – by Route of Administration. 33
- 1.3.4 Global Biosimilars Market – by End User 33
- 1.3.5 Global Biosimilars Market – by Geography. 33
- 2. Biosimilars Market – Key Takeaways 35
- 3. Research Methodology 42
- 3.1 Coverage. 43
- 3.2 Secondary Research. 43
- 3.3 Primary Research. 43
- 4. Biosimilars Market – Market Landscape 45
- 4.1 Overview.. 45
- 4.2 PEST Analysis. 45
- 4.2.1 North America PEST Analysis. 45
- 4.2.2 Europe PEST Analysis. 46
- 4.2.3 Asia Pacific PEST Analysis. 46
- 4.2.4 South & Central America PEST Analysis. 47
- 4.2.5 Middle East & Africa PEST Analysis. 47
- 4.3 Expert’s Opinion. 48
- 5. Biosimilars Market – Key Market Dynamics 49
- 5.1 Market Drivers. 49
- 5.1.1 Increasing Prevalence of Chronic Diseases. 49
- 5.1.2 Cost Effectiveness of Biosimilar Drugs. 49
- 5.1.3 Rising Approvals of Biosimilars. 50
- 5.2 Market Restraints. 51
- 5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing. 51
- 5.3 Market Opportunities. 52
- 5.3.1 Patent Expiry of Blockbuster Biologics. 52
- 5.4 Future Trend. 53
- 5.4.1 Collaborations for Biosimilars and Clinical Trials. 53
- 5.5 Impact analysis. 54
- 6. Biosimilars Market – Global Analysis 55
- 6.1 Global Biosimilars Market Revenue Forecast and Analysis. 55
- 6.2 Global Biosimilars Market, by Geography – Forecast and Analysis. 56
- 6.3 Market Positioning of Key Players. 57
- 7. Global Biosimilars Market – Revenue and Forecast to 2028 – by Disease Indication 58
- 7.1 Overview.. 58
- 7.2 Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%) 58
- 7.3 Cancer 59
- 7.3.1 Overview.. 59
- 7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 59
- 7.4 Diabetes. 60
- 7.4.1 Overview.. 60
- 7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 60
- 7.5 Autoimmune Diseases. 61
- 7.5.1 Overview.. 61
- 7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 61
- 7.5.3 Psoriasis: 62
- 7.5.3.1 Overview.. 62
- 7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 62
- 7.5.4 Arthritis: 63
- 7.5.4.1 Overview.. 63
- 7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 63
- 7.5.5 Others: 64
- 7.5.5.1 Overview.. 64
- 7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 64
- 7.6 Others Disease Indications. 65
- 7.6.1 Overview.. 65
- 7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 65
- 8. Global Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration 66
- 8.1 Overview.. 66
- 8.2 Global Biosimilars Market, by Application 2021 & 2028 (%) 66
- 8.3 Intravenous. 67
- 8.3.1 Overview.. 67
- 8.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 67
- 8.4 Subcutaneous. 68
- 8.4.1 Overview.. 68
- 8.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 68
- 8.5 Others. 69
- 8.5.1 Overview.. 69
- 8.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 69
- 9. Global Biosimilars Market – Revenue and Forecast to 2028 – by End User 70
- 9.1 Overview.. 70
- 9.2 Biosimilars Market Revenue Share, by End User 2021 & 2028 (%) 70
- 9.3 Hospitals. 71
- 9.3.1 Overview.. 71
- 9.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 71
- 9.4 Specialty Clinics. 72
- 9.4.1 Overview.. 72
- 9.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 72
- 9.5 Homecare. 73
- 9.5.1 Overview.. 73
- 9.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 73
- 9.6 Other 74
- 9.6.1 Overview.. 74
- 9.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 74
- 10. Biosimilars Market – Revenue and Forecast to 2028 – Geographic Analysis 75
- 10.1 North America: Biosimilar Market Europe. 75
- 10.1.1 Overview.. 75
- 10.1.2 North America: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 76
- 10.1.3 North America: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 76
- 10.1.3.1 North America: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 77
- 10.1.4 North America: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 77
- 10.1.5 North America: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 78
- 10.1.6 North America: Biosimilar Market, by End User, 2019–2028 (US$ Million) 78
- 10.1.7 North America: Biosimilar Market, by Country, 2021 & 2028 (%) 79
- 10.1.7.1 US: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 79
- 10.1.7.1.1 Overview.. 79
- 10.1.7.1.2 US: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 80
- 10.1.7.1.3 US: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 80
- 10.1.7.1.3.1 US: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 81
- 10.1.7.1.4 US: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 81
- 10.1.7.1.5 US: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 82
- 10.1.7.1.6 US: Biosimilar Market, by End User, 2019–2028 (US$ Million) 82
- 10.1.7.2 Canada: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 83
- 10.1.7.2.1 Canada: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 83
- 10.1.7.2.2 Canada: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 84
- 10.1.7.2.2.1 Canada: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 84
- 10.1.7.2.3 Canada: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 85
- 10.1.7.2.4 Canada: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 85
- 10.1.7.2.5 Canada: Biosimilar Market, by End User, 2019–2028 (US$ Million) 86
- 10.1.7.3 Mexico: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 87
- 10.1.7.3.1 Mexico: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 87
- 10.1.7.3.2 Mexico: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 88
- 10.1.7.3.2.1 Mexico: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 88
- 10.1.7.3.3 Mexico: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 88
- 10.1.7.3.4 Mexico: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 89
- 10.1.7.3.5 Mexico: Biosimilar Market, by End User, 2019–2028 (US$ Million) 89
- 10.2 Europe: Biosimilars Market 90
- 10.2.1 Overview.. 90
- 10.2.2 Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 91
- 10.2.3 Europe: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 91
- 10.2.3.1 Europe: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 92
- 10.2.4 Europe: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 92
- 10.2.5 Europe: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 92
- 10.2.6 Europe: Biosimilars Market, by End User, 2019–2028 (US$ Million) 93
- 10.2.7 Europe: Biosimilars Market, by Country, 2021 & 2028 (%) 93
- 10.2.7.1 Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 94
- 10.2.7.1.1 Overview.. 94
- 10.2.7.1.2 Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 94
- 10.2.7.1.3 Germany: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 95
- 10.2.7.1.3.1 Germany: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 95
- 10.2.7.1.4 Germany: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 96
- 10.2.7.1.5 Germany: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 96
- 10.2.7.1.6 Germany Biosimilars Market, by End User, 2019–2028 (US$ Million) 96
- 10.2.7.2 UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 97
- 10.2.7.2.1 Overview.. 97
- 10.2.7.2.2 UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 97
- 10.2.7.2.3 UK: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 98
- 10.2.7.2.3.1 UK: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 98
- 10.2.7.2.4 UK: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 99
- 10.2.7.2.5 UK: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 99
- 10.2.7.2.6 UK: Biosimilars Market, by End User, 2019–2028 (US$ Million) 100
- 10.2.7.3 France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 101
- 10.2.7.3.1 Overview.. 101
- 10.2.7.3.2 France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 101
- 10.2.7.3.3 France: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 102
- 10.2.7.3.3.1 France: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 102
- 10.2.7.3.4 France: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 102
- 10.2.7.3.5 France: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 103
- 10.2.7.3.6 France: Biosimilars Market, by End User, 2019–2028 (US$ Million) 103
- 10.2.7.4 Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 104
- 10.2.7.4.1 Overview.. 104
- 10.2.7.4.2 Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 104
- 10.2.7.4.3 Italy: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 105
- 10.2.7.4.3.1 Italy: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 105
- 10.2.7.4.4 Italy: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 105
- 10.2.7.4.5 Italy: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 106
- 10.2.7.4.6 Italy: Biosimilars Market, by End User, 2019–2028 (US$ Million) 106
- 10.2.7.5 Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 107
- 10.2.7.5.1 Overview.. 107
- 10.2.7.5.2 Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 107
- 10.2.7.5.3 Spain: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 108
- 10.2.7.5.3.1 Spain: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 109
- 10.2.7.5.4 Spain: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 109
- 10.2.7.5.5 Spain: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 109
- 10.2.7.5.6 Spain: Biosimilars Market, by End User, 2019–2028 (US$ Million) 110
- 10.2.7.6 Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 111
- 10.2.7.6.1 Overview.. 111
- 10.2.7.6.2 Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 111
- 10.2.7.6.3 Rest of Europe: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 112
- 10.2.7.6.3.1 Rest of Europe: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 112
- 10.2.7.6.4 Rest of Europe: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 112
- 10.2.7.6.5 Rest of Europe: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 113
- 10.2.7.6.6 Rest of Europe: Biosimilars Market, by End User, 2019–2028 (US$ Million) 113
- 10.3 Asia Pacific: Biosimilars Market 114
- 10.3.1 Overview.. 114
- 10.3.2 Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 115
- 10.3.3 Asia Pacific: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 115
- 10.3.3.1 Asia Pacific: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 116
- 10.3.4 Asia Pacific: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 116
- 10.3.5 Asia Pacific: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 117
- 10.3.6 Asia Pacific: Biosimilars Market, by End User, 2019–2028 (US$ Million) 117
- 10.3.7 Asia Pacific: Biosimilars Market, by Country, 2021 & 2028 (%) 117
- 10.3.7.1 China: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 118
- 10.3.7.1.1 Overview.. 118
- 10.3.7.1.2 China: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 118
- 10.3.7.1.3 China: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 119
- 10.3.7.1.3.1 China: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 119
- 10.3.7.1.4 China: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 120
- 10.3.7.1.5 China: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 120
- 10.3.7.1.6 China Biosimilars Market, by End User, 2019–2028 (US$ Million) 120
- 10.3.7.2 Japan: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 121
- 10.3.7.2.1 Overview.. 121
- 10.3.7.2.2 Japan: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 121
- 10.3.7.2.3 Japan: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 122
- 10.3.7.2.3.1 Japan: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 122
- 10.3.7.2.4 Japan: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 123
- 10.3.7.2.5 Japan: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 123
- 10.3.7.2.6 Japan: Biosimilars Market, by End User, 2019–2028 (US$ Million) 123
- 10.3.7.3 India: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 124
- 10.3.7.3.1 Overview.. 124
- 10.3.7.3.2 India: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 124
- 10.3.7.3.3 India: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 125
- 10.3.7.3.3.1 India: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 125
- 10.3.7.3.4 India: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 125
- 10.3.7.3.5 India: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 126
- 10.3.7.3.6 India: Biosimilars Market, by End User, 2019–2028 (US$ Million) 126
- 10.3.7.4 South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 127
- 10.3.7.4.1 Overview.. 127
- 10.3.7.4.2 South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 127
- 10.3.7.4.3 South Korea: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 127
- 10.3.7.4.3.1 South Korea: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 128
- 10.3.7.4.4 South Korea: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 128
- 10.3.7.4.5 South Korea: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 129
- 10.3.7.4.6 South Korea: Biosimilars Market, by End User, 2019–2028 (US$ Million) 129
- 10.3.7.5 Australia: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 130
- 10.3.7.5.1 Overview.. 130
- 10.3.7.5.2 Australia: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 130
- 10.3.7.5.3 Australia: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 130
- 10.3.7.5.3.1 Australia: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 131
- 10.3.7.5.4 Australia: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 131
- 10.3.7.5.5 Australia: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 132
- 10.3.7.5.6 Australia: Biosimilars Market, by End User, 2019–2028 (US$ Million) 132
- 10.3.7.6 Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 133
- 10.3.7.6.1 Overview.. 133
- 10.3.7.6.2 Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 133
- 10.3.7.6.3 Rest of Asia Pacific: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 134
- 10.3.7.6.3.1 Rest of Asia Pacific: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 134
- 10.3.7.6.4 Rest of Asia Pacific: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 135
- 10.3.7.6.5 Rest of Asia Pacific: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 135
- 10.3.7.6.6 Rest of Asia Pacific: Biosimilars Market, by End User, 2019–2028 (US$ Million) 135
- 10.4 Middle East and Africa: Biosimilars Market 137
- 10.4.1 Overview.. 137
- 10.4.2 Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 138
- 10.4.3 Middle East and Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 138
- 10.4.3.1 Middle East and Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 139
- 10.4.4 Middle East and Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 139
- 10.4.5 Middle East and Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 139
- 10.4.6 Middle East and Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million) 140
- 10.4.7 Middle East and Africa: Biosimilar Market, by Country, 2021 & 2028 (%) 140
- 10.4.7.1 Saudi Arabia: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 141
- 10.4.7.1.1 Overview.. 141
- 10.4.7.1.2 Saudi Arabia: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 141
- 10.4.7.1.3 Saudi Arabia: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 142
- 10.4.7.1.3.1 Saudi Arabia: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 142
- 10.4.7.1.4 Saudi Arabia: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 142
- 10.4.7.1.5 Saudi Arabia: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 143
- 10.4.7.1.6 Saudi Arabia: Biosimilar Market, by End User, 2019–2028 (US$ Million) 143
- 10.4.7.2 South Africa: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 144
- 10.4.7.2.1 South Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 144
- 10.4.7.2.2 South Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 145
- 10.4.7.2.2.1 South Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 145
- 10.4.7.2.3 South Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 145
- 10.4.7.2.4 South Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 146
- 10.4.7.2.5 South Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million) 146
- 10.4.7.3 UAE: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 147
- 10.4.7.3.1 UAE: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 147
- 10.4.7.3.2 UAE: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 148
- 10.4.7.3.2.1 UAE: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 148
- 10.4.7.3.3 UAE: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 148
- 10.4.7.3.4 UAE: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 149
- 10.4.7.3.5 UAE: Biosimilar Market, by End User, 2019–2028 (US$ Million) 149
- 10.4.7.4 Rest of Middle East and Africa: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million) 150
- 10.4.7.4.1 Rest of Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million) 150
- 10.4.7.4.2 Rest of Middle East and Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million) 150
- 10.4.7.4.2.1 Rest of Middle East and Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 151
- 10.4.7.4.3 Rest of Middle East and Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million) 151
- 10.4.7.4.4 Rest of Middle East and Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million) 152
- 10.4.7.4.5 Rest of Middle East and Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million) 152
- 10.5 South & Central America Biosimilars Market 153
- 10.5.1 Overview.. 153
- 10.5.2 South & Central America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 153
- 10.5.3 South & Central America: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 154
- 10.5.3.1 South & Central America: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 154
- 10.5.4 South & Central America: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 154
- 10.5.5 South & Central America: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 155
- 10.5.6 South & Central America: Biosimilars Market, by End User, 2019–2028 (US$ Million) 155
- 10.5.7 South & Central America: Biosimilars Market, by Country, 2021 & 2028 (%) 156
- 10.5.7.1 Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 156
- 10.5.7.1.1 Overview.. 156
- 10.5.7.1.2 Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 156
- 10.5.7.1.3 Brazil: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 157
- 10.5.7.1.3.1 Brazil: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 157
- 10.5.7.1.4 Brazil: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 157
- 10.5.7.1.5 Brazil: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 158
- 10.5.7.1.6 Brazil: Biosimilars Market, by End User, 2019–2028 (US$ Million) 158
- 10.5.7.2 Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 159
- 10.5.7.2.1 Overview.. 159
- 10.5.7.2.2 Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 159
- 10.5.7.2.3 Argentina: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 159
- 10.5.7.2.3.1 Argentina: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 160
- 10.5.7.2.4 Argentina: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 160
- 10.5.7.2.5 Argentina: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 161
- 10.5.7.2.6 Argentina: Biosimilars Market, by End User, 2019–2028 (US$ Million) 161
- 10.5.7.3 Rest of South & Central America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 162
- 10.5.7.3.1 Overview.. 162
- 10.5.7.3.2 Rest of South & Central America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million) 162
- 10.5.7.3.3 Rest of South & Central America: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million) 163
- 10.5.7.3.3.1 Rest of South & Central America: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million) 163
- 10.5.7.3.4 Rest of South & Central America: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million) 164
- 10.5.7.3.5 Rest of South & Central America: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million) 164
- 10.5.7.3.6 Rest of South & Central America: Biosimilars Market, by End User, 2019–2028 (US$ Million) 165
- 11. Biosimilars Market – Industry Landscape 166
- 11.1 Overview.. 166
- 11.2 Growth Strategies in the Biosimilars Market 166
- 11.3 Inorganic Growth Strategies. 167
- 11.3.1 Overview.. 167
- 11.4 Organic Growth Strategies. 169
- 11.4.1 Overview.. 169
- 12. Company Profiles 172
- 12.1 Amgen Inc. 172
- 12.1.1 Key Facts. 172
- 12.1.2 Business Description. 172
- 12.1.3 Products and Services. 172
- 12.1.4 Financial Overview.. 173
- 12.1.5 SWOT Analysis. 175
- 12.1.6 Key Developments. 175
- 12.2 Celltrion Inc. 176
- 12.2.1 Key Facts. 176
- 12.2.2 Business Description. 176
- 12.2.3 Products and Services. 176
- 12.2.4 Financial Overview.. 176
- 12.2.5 SWOT Analysis. 178
- 12.2.6 Key Developments. 179
- 12.3 Sanofi SA. 180
- 12.3.1 Key Facts. 180
- 12.3.2 Business Description. 180
- 12.3.3 Products and Services. 181
- 12.3.4 Financial Overview.. 181
- 12.3.5 SWOT Analysis. 183
- 12.3.6 Key Developments. 183
- 12.4 Biocon Ltd. 184
- 12.4.1 Key Facts. 184
- 12.4.2 Business Description. 184
- 12.4.3 Products and Services. 184
- 12.4.4 Financial Overview.. 185
- 12.4.5 SWOT Analysis. 186
- 12.4.6 Key Developments. 187
- 12.5 Samsung Bioepis Co Ltd. 188
- 12.5.1 Key Facts. 188
- 12.5.2 Business Description. 188
- 12.5.3 Products and Services. 188
- 12.5.4 Financial Overview.. 188
- 12.5.5 SWOT Analysis. 189
- 12.5.6 Key Developments. 190
- 12.6 Coherus BioSciences Inc. 191
- 12.6.1 Key Facts. 191
- 12.6.2 Business Description. 191
- 12.6.3 Products and Services. 191
- 12.6.4 Financial Overview.. 191
- 12.6.5 SWOT Analysis. 193
- 12.6.6 Key Developments. 194
- 12.7 Eli Lilly and Co. 195
- 12.7.1 Key Facts. 195
- 12.7.2 Business Description. 195
- 12.7.3 Products and Services. 196
- 12.7.4 Financial Overview.. 196
- 12.7.5 SWOT Analysis. 198
- 12.7.6 Key Developments. 198
- 12.8 Sandoz AG.. 199
- 12.8.1 Key Facts. 199
- 12.8.2 Business Description. 199
- 12.8.3 Products and Services. 199
- 12.8.4 Financial Overview.. 199
- 12.8.5 SWOT Analysis. 200
- 12.8.6 Key Developments. 201
- 12.9 Teva Pharmaceutical Industries Ltd. 202
- 12.9.1 Key Facts. 202
- 12.9.2 Business Description. 202
- 12.9.3 Products and Services. 203
- 12.9.4 Financial Overview.. 203
- 12.9.5 SWOT Analysis. 205
- 12.9.6 Key Developments. 205
- 12.10 Pfizer Inc. 206
- 12.10.1 Key Facts. 206
- 12.10.2 Business Description. 206
- 12.10.3 Products and Services. 207
- 12.10.4 Financial Overview.. 207
- 12.10.5 SWOT Analysis. 209
- 12.10.6 Key Developments. 209
- 12.11 Dr. Reddy's Laboratories Ltd. 210
- 12.11.1 Key Facts. 210
- 12.11.2 Business Description. 210
- 12.11.3 Products and Services. 210
- 12.11.4 Financial Overview.. 211
- 12.11.5 SWOT Analysis. 212
- 12.11.6 Key Developments. 212
- 13. Appendix 214
- 13.1 About The Insight Partners. 214
- 13.2 Glossary of Terms. 214
- LIST OF TABLES
- Table 1. Comparison Between Different Drug Developments. 51
- Table 2. North America Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 76
- Table 3. North America Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 77
- Table 4. North America Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 77
- Table 5. North America Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 78
- Table 6. North America Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million) 78
- Table 7. US Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 80
- Table 8. US Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 81
- Table 9. US Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 81
- Table 10. US Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 82
- Table 11. US Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million) 82
- Table 12. Canada Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 84
- Table 13. Canada Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 84
- Table 14. Canada Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 85
- Table 15. Canada Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 85
- Table 16. Canada Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million) 86
- Table 17. Mexico Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 88
- Table 18. Mexico Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 88
- Table 19. Mexico Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 88
- Table 20. Mexico Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 89
- Table 21. Mexico Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million) 89
- Table 22. Europe Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 91
- Table 23. Europe Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 92
- Table 24. Europe Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 92
- Table 25. Europe Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 92
- Table 26. Europe Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million) 93
- Table 27. Germany Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 95
- Table 28. Germany Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 95
- Table 29. Germany Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 96
- Table 30. Germany Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 96
- Table 31. Germany Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million) 96
- Table 32. UK Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 98
- Table 33. UK Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 98
- Table 34. UK Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 99
- Table 35. UK Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 99
- Table 36. UK Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million) 100
- Table 37. France Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 102
- Table 38. France Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 102
- Table 39. France Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 102
- Table 40. France Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 103
- Table 41. France Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million) 103
- Table 42. Italy Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million) 105
- Table 43. Italy Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million) 105
- Table 44. Italy Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million) 105
- Table 45. Italy Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million) 106
- Table 46. Italy Biosimilars Market, by End User – Revenue and Fore
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
